

AMENDMENTS TO THE CLAIMS

1. (Currently amended) A An isolated human monoclonal antibody, or binding fragment thereof, that binds to phospholipase A2 (PLA2) and comprises a heavy chain having an amino acid sequence selected from the group consisting of SEQ ID NOS: 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 30, and 31.

2. (Original) The antibody of Claim 1, further comprising a light chain having an amino acid sequence selected from the group consisting of SEQ ID NOS: 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, and 28.

3. (Original) The human monoclonal antibody of Claim 2, wherein the heavy chain has an amino sequence comprising the sequence of SEQ ID NO:3 and the light chain has an amino sequence comprising the sequence of SEQ ID NO:4.

4. (Original) The human monoclonal antibody of Claim 2, wherein the heavy chain has an amino sequence comprising the sequence of SEQ ID NO:5 and the light chain has an amino sequence comprising the sequence of SEQ ID NO:6.

5. (Original) The human monoclonal antibody of Claim 2, wherein the heavy chain has an amino sequence comprising the sequence of SEQ ID NO:7 and the light chain has an amino sequence comprising the sequence of SEQ ID NO:8.

6. (Original) The human monoclonal antibody of Claim 2, wherein the heavy chain has an amino sequence comprising the sequence of SEQ ID NO:9 and the light chain has an amino sequence comprising the sequence of SEQ ID NO:10.

7. (Original) The human monoclonal antibody of Claim 2, wherein the heavy chain has an amino sequence comprising the sequence of SEQ ID NO:11 and the light chain has an amino sequence comprising the sequence of SEQ ID NO:12.

8. (Original) The human monoclonal antibody of Claim 2, wherein the heavy chain has an amino sequence comprising the sequence of SEQ ID NO:13 and the light chain has an amino sequence comprising the sequence of SEQ ID NO:14.

9. (Original) The human monoclonal antibody of Claim 2, wherein the heavy chain has an amino sequence comprising the sequence of SEQ ID NO:15 and the light chain has an amino sequence comprising the sequence of SEQ ID NO:16.

Appl. No. : 10/726,332
Filed : December 2, 2003

10. (Original) The human monoclonal antibody of Claim 2, wherein the heavy chain has an amino sequence comprising the sequence of SEQ ID NO:17 and the light chain has an amino sequence comprising the sequence of SEQ ID NO:18.

11. (Original) The human monoclonal antibody of Claim 2, wherein the heavy chain has an amino sequence comprising the sequence of SEQ ID NO:19 and the light chain has an amino sequence comprising the sequence of SEQ ID NO:20.

12. (Original) The human monoclonal antibody of Claim 2, wherein the heavy chain has an amino sequence comprising the sequence of SEQ ID NO:21 and the light chain has an amino sequence comprising the sequence of SEQ ID NO:22.

13. (Original) The human monoclonal antibody of Claim 2, wherein the heavy chain has an amino sequence comprising the sequence of SEQ ID NO:23 and the light chain has an amino sequence comprising the sequence of SEQ ID NO:24.

14. (Original) The human monoclonal antibody of Claim 2, wherein the heavy chain has an amino sequence comprising the sequence of SEQ ID NO:25 and the light chain has an amino sequence comprising the sequence of SEQ ID NO:26.

15. (Original) The human monoclonal antibody of Claim 2, wherein the heavy chain has an amino sequence comprising the sequence of SEQ ID NO:27 and the light chain has an amino sequence comprising the sequence of SEQ ID NO:28.

16. **(Currently amended)** An isolated antibody, or binding fragment thereof, immobilized on an insoluble matrix, wherein the antibody is the antibody of Claim 2.

17. **(Withdrawn)** A method for assaying the level of phospholipase A2 (PLA2) in a patient sample, wherein said method comprises the use of the anti-PLA2 antibody of Claim 2 for detection of the level of PLA2 in the assay of a patient sample.

18. **(Withdrawn)** The method according to Claim 17 wherein the patient sample is blood.

19. (Original) A composition comprising the antibody of Claim 2, or a binding fragment thereof, and a pharmaceutically acceptable carrier.

20. **(Withdrawn)** A method of effectively treating inflammatory conditions, comprising:

selecting an animal in need of treatment for an inflammatory condition; and

administering to said animal a therapeutically effective dose of an antibody, or binding fragment thereof, that specifically binds to phospholipase A2 (PLA2).

21. **(Withdrawn)** The method of Claim 20, wherein said animal is human.

22. **(Withdrawn)** The method of Claim 20, where said antibody is a fully human monoclonal antibody.

23. **(Withdrawn)** The method of Claim 20, wherein said inflammatory condition is selected from the group consisting of: inflammatory and degenerative disorders stemming from inflammatory reactions in the joints, skin, and blood vessels, arthritis, psoriasis, asthma, Alzheimer's disease, atherosclerosis, and restenosis.

24. **(Withdrawn)** The method of Claim 20, wherein the antibody is the antibody of Claim 2.

25. **(Withdrawn)** A method of effectively treating restinosis, comprising:
selecting an animal in need of treatment for an inflammatory condition; and
administering to said animal a therapeutically effective dose of an antibody, or binding fragment thereof, that specifically binds to phospholipase A2 (PLA2).

26. **(Withdrawn)** The method of Claim 25, wherein said animal is human.

27. **(Withdrawn)** The method of Claim 25, wherein said antibody is a fully human monoclonal antibody.

28. **(Withdrawn)** The method of Claim 25, wherein the antibody is the antibody of Claim 2.

29. **(New)** The antibody of Claim 1, wherein said binding fragment is selected from the group consisting of Fab, Fab', F(ab')₂, and Fv.

30. **(New)** The antibody of Claim 16, wherein said binding fragment is selected from the group consisting of Fab, Fab', F(ab')₂, and Fv.

31. **(New)** The antibody of Claim 19, wherein said binding fragment is selected from the group consisting of Fab, Fab', F(ab')₂, and Fv.